Form 4/A for RMD ResMed|
Accepted 2023-11-20 00:00:00 ET · period of report 2023-11-16 · accession 0001127602-23-028095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2023-11-20 | 2023-11-16 | RMD | Farrell Michael J. | CEO | M - OptEx | $57.76 | +3,462 | 444.4K | +0.8% | +$200.0K |
| DMA | 2023-11-20 | 2023-11-16+ | RMD | Farrell Michael J. | CEO | F - Tax | $148.93 | -3,696 | 443.1K | -0.8% | -$550.4K |
| DA | 2023-11-20 | 2023-11-16 | RMD | Farrell Michael J. | CEO | A - Grant | $148.90 | +55.5K | 55.5K | New | +$8.26M |
| DA | 2023-11-20 | 2023-11-16 | RMD | Farrell Michael J. | CEO | M - OptEx | $0.00 | -3,462 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2023-11-16 | M | A | 3,462 | $57.76 | 444,448 | D | — | — | |
| 2 | Common | ResMed Common Stock | 2023-11-20 | F | D | 2,352.93 | $148.94 | 440,752 | D | — | — | |
| 3 | Common | ResMed Common Stock | 2023-11-16 | F | D | 1,343 | $148.90 | 443,105 | D | — | — | |
| 4 | Derivative | ResMed Common Stock Options | 2023-11-16 | A | A | 55,468 | $148.90 | 55,468 | D | $148.90 · 2024-11-11 to 2030-11-16 | 55,468 ResMed Common Stock | (F5) Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026. |
| 5 | Derivative | ResMed Common Stock Options | 2023-11-16 | M | D | 3,462 | $0.00 | 0 | D | $57.76 · 2017-11-11 to 2023-11-16 | 3,462 ResMed Common Stock |